Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors.
Dromain C, Pavel M, Ronot M, Schaefer N, Mandair D, Gueguen D, Cheng C, Dehaene O, Schutte K, Cahané D, Jégou S, Balazard F.
Dromain C, et al. Among authors: mandair d.
Future Oncol. 2023 Oct;19(32):2171-2183. doi: 10.2217/fon-2022-1137. Epub 2023 Jul 27.
Future Oncol. 2023.
PMID: 37497626